APA (7th ed.) Citation

DK, H., D, D., H, M., J, D., R, B., T, O., . . . KK, P. (2026). Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: A CIBMTR study. Blood cancer journal, 16(1), . https://doi.org/10.1038/s41408-026-01496-w

Chicago Style (17th ed.) Citation

DK, Hansen, et al. "Safety and Efficacy of Ciltacabtagene Autoleucel for Relapsed/refractory Multiple Myeloma: A CIBMTR Study." Blood Cancer Journal 16, no. 1 (2026). https://doi.org/10.1038/s41408-026-01496-w.

MLA (9th ed.) Citation

DK, Hansen, et al. "Safety and Efficacy of Ciltacabtagene Autoleucel for Relapsed/refractory Multiple Myeloma: A CIBMTR Study." Blood Cancer Journal, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41408-026-01496-w.